Summary: External quality assessment programmes for specific IgE have been organised for some years in the United Kingdom, Belgium and the Netherlands but independently. This paper describes a co-operation scheine whereby the same samples were circulated simultaneously from each of the three countries and subsequent results combined to produce a single "EURO EQAS" report.
Introduction
ment schemes. The good inter-assay and inter-laboratory agreement of total serum IgE measurements indicates In 1967, IgE was defined äs a fifth distinct human im-^ ^ measurement does not present a major technical munoglobulin and it was shown to be the reaginic anti-challenge to regulated diagnostic allergy laboratories body (l, 2). Shortly thereafter, serological assays were and therefore discussion of quality assurance schemes developed to quantify the total leVel of IgE and to detect for ^ analyte wiu be excluded in this papen Rathei . the presence of allergen-specific IgE antibodies in serum Ae emphasis of this ove rview will be on quality assur- (3) . Today, diagnostic laboratories throughout the world ance scheme s that evaluate the results from laboratories analyseserafromindividualssuspectedofhavingätopic that perform allergen specific IgE antibody measuredisease using a spectrum of immunochemical reagents ments using a va riety of serological immunoassays. The and a variety of isotopic and non-isötopic immunoassays goa i o f this report is to describe the results produced by (4, 5) . The commercially available immunoassays for to-laboratories in the United Kingdom, Belgium and the tal serum IgE have reached a high level of agreement Netherlands where a co-operative EURO EQAS is curbetween methods and laboratories accordiiig to past rently in Operation. Problems associated with the arbiquality assurance schemes: this is primarily due to the trary nature of IgE antibody assay reporting methods availability of well cha ! racterised anti^human IgE re-that ultimately prevent effective inter-assay comparisons agents, internationally recognised human IgE reference will be highlighted. The programme will be examined preparations and widely used exteraal quality assess-within the context of repräsentative results generated by participants of the surveys during the 1992 cycle of distributions.
Allergen-Spccific IgE Immunoassay Methods
Commercially available allergen specific IgE antibody immunoassays are in a state of constant transition äs a result of continual improvements in reagent quality, assay design and automated Instrumentation. The earliest semi-quantitative non-competitive binding solid phase immunoradiometric assay for IgE antibody was a procedure called the radioallergosorbent test or RAST. Second generation assays have been providing laboratories with less labour-intensive procedures that are more automated, non-isotopic and that use microprocessor-driven Instruments. Despite the changes in reagents and Instrumentation the majority of available commercial allergen-specific IgE assays are considered highly complex assays that require skilled technical staff.
IgE antibody immunoassays may be viewed simplistically äs being composed of two major attributes. The first and generally less problematic characteristic of IgE antibody assays is their ability to detect nanogram quantities of IgE, often in the presence of microgram quantities of other immunoglobulins (e. g. IgG) and while this has posed a substantial challenge the analytical sensitivity of most immunoassays today are able to cope with this pröbleni. The second and more variable characteristic of these assays relates to the allergen specificity of the antibody detected in the assay äs humans can exhibit immediate-type hypersensitivity to over 300 naturally occurring substances that are extractable from the pollens of trees, grasses and weeds and components released from animals, moulds, insects and foods.
The same crude allergen-containing raw material can be processed differently by two manufacturers, yielding allergen-containing assay reagents that vary widely in their allergenic potency and specificity. The allergen component of the assay must therefore be considered that reagent that produces the greatest variability in IgE antibody measurements obtained with different commercially available methods.
The overall performance of a particular laboratory in the exteraal quality assurance schemes discussed subsequently depends on multiple inter-related variables. Besides the quality of the immunoassay (reagents and procedures) themselves, other important variables include the technical capability of the staff, intemal quality control procedures and uncontrolled random errors that can occur during the analysis. If a laboratory is out of control or it produces IgE antibody results that do not agree with those produced by other laboratories using the same method, then the assay and these other associated variables need to be examined to identify the problem.
Aims of the Euro EQAS for Allergen Specific IgE Antibody Assays
The aims of the external quality assessment schemes in each of the three countries were similar but it was feit that ä co^operative scheme could have many advantages. It was hoped to involve a maximal number of laboratories that are performing specific IgE immunoassays regardless of the size of the laboratory or their method in use. Also the improved size of the database would help useful analysis of data for those laboratories using the less populär commercial methods. As of 1992 the EuroEQAS had 221 participants growing to 239 by the end of the year (the number of participants and the methods in use can be seen in table 1). This scheme collates qualitative "grade or class" and semiquantitative "unit" measurements that reflect the presence and relative amount of IgE antibody in a particular serum specimen. Differ. ences in the results produced by a single laboratory can be compared to a "group mean" produced by participants using the same method. In this scheme differences in specific IgE antibody results for a partieular method are examined between countries and within a laboratory by analysis of the same specimen up to 4 times within a year. The ultimate goal of this scherne is to promote agreement or unanimity of group results such that the majority of laboratories performing a particular allergen specificity/assay eombination agree that a specimen either does or does not contain specific IgE antibody (and also ifpossible. agree on the relative "concentration" of a particular IgE antibody). The quality assessment attempts to use the Information to identify problem assays and laboratories and remains flexible in order to modify the scheme design in order to improve both inter-rnethod and inter^läboratory ständardisätion.
In all specific IgE antibody assays ä class 0 is defmed äs the absence of specific IgE antibody in the serum whilst classes l through 6 show increasing concentrations of the specific IgE antibody and they have been shown to be associated with increasing clinical sensitivity to the allergen in questipn.
In this quality assurance scheme it has been diffieult to evaluate laboratory performance with IgE antibody results in class data except in a gross manner. Borderline results are diffieult to Interpret except when the serum specimen is known to have no IgE antibody to that allergen specificity. Information about the performance of the laboratory and the assay method that it uses in detecting a spectrum of low to high levels in IgE antibody positive specimens can be lost when the scheme uses only class scoring analysis. Most IgE antibody assays also provide a more quantitative unitage assignment of IgE antibody which is based on total serum IgE or an allergen specific antibody reference curve that has been constructed with a calibration serum assigned an arbitrary number of "units".
IgE antibody levels in test specimens can then be reported in the same "units" interpolated from this reference cürve. At preserit'the quantitative relationship between the arbitrary units used by the various commercial assays is not known. Thus, cornparisons of the levels of IgE antibody reported by the participants in units using a variety of commercial methods can be viewed only within a method group and not between method groups.
Survey Design and Sample Specifications
Four serum pools containing prescribed specific IgE antibodies were prepared at the serum bank of Pharmacia (Uppsala, Sweden) and each poql contained specific antibodies to four different allergens at varying coneentration levefs. In addition each pool was ascribed a "negative allergen" one which the pool was known not to contain (see tab. 2).
Three samples were distributed every 6 weeks by the national scheme organisers and the participants were asked to test against three named allergens in each sample and participants had to report their results within 5 weeks. This randomised sampling enabled the identity of each pool to be kept secret from the participants on receipt of their samples.
Over the period of 1992 eight distributions were undertaken and each pool was circtilated on 6 occasions and each allergen in each pool was tested either 3 or 4 times.
Results from each participant were sent in the flrst instance to their national organiser who issued national reports only within their country and then all results were sent to the EURO organiser who is based in the UK and then a EURO report was issued to all participants.
The allergens chosen for analysis represented a cross-section of the 10 or so most common allergens in Western Europe and the most common allergens were represented in more than one serum pool at varying concentrations of IgE antibody level. The scheme was anonymous in that each participant was identifled by a number with no organiser knowing the identity of all the participants in the scheme.
Data Analysis and Calculations
Results were analysed by sample number and by individual allergens within a sample. As mentioned earlier results were analysed by class or grade and by units and divided by method.
Results by grade were analysed äs an overall group and then by method so that participants could see these results äs the number of participants reporting each grade äs a group and also by method.
Results in units were analysed using the variance index scoring System (described fully by Bullock & Wilde (6)) using the group laboratory trimmed mean äs the designated value for each allergenspecific antibody.
For each allergen-specific antibody a bias index score is calculated for each laboratory and this is used to calculate the mean running variance index score for each allergen specific antibody and overall mean running index score which represents an overall performance tab. 
Results

(a) By grades
The results in grades for each allergen-specific antibody in each of the 4 pools circulated are shown in table 4 and they show that in the majority of cases almost all the laboratories were able to identify those allergens present and those absent in the 4 serum pools. The Pharmacia CAP method in the main reported higher grades to each allergen compared to the Pharmacia RAST and other methods in use but in some of the allergens a low concentration of antibody did result in some methods 
Mean running variance index score:
The mean of the variance index scores in the current analytical time window (for most analytes this will be the last 4 results).
Bias index score: Identical to the variance index score but retaining the sign; a result higher than the designated value will give a positive bias index score, whilst a lower result will give a negative bias index score.
Mean running bias index score:
The arithmetic mean of the bias index scores in the current analytical time window.
Standard deviation ofthe bias index score: The Standard deviation (SD) ofthe bias index scores in the current analytical time window.
Designated value: For this scheme and analytes this is the method laboratory trimmed mean.
All laboratory trimmed mean:
The recalculated mean value after exclusion of all results outside 3 SD from the all trimmed laboratory mean. In this scheme the trimming is perfonned at the 7.5th and 92.5th centiles.
Chosen coefficients of Variation:
A scaling factor for each analyte to correct for the current state of the art so äs to produce variance index scores in a "common currency". The chosen coefficient of Variation does not represent a "clinically acccptable error".
Overall mean ninning variance index score:
The mean of the 24 most recent variance index scores irrespective of analyte for each laboratory (minimum of 12 results required for calculation).
Tab. 4 Rcsults in grades by serum pool (SP) and allergen. A point showing a difference of allergen recognition was shown in the results to "house dust inite" present in pools SP01 and SP04 where Pharmacia CAP users report positive grades in both pools but DPC users report positive grades in pool SP01 but negative grades in pool SP04 (tab. 5).
(b) By units
A particular laboratories performance can in theory be more rigorously evaluated with unit results interpolated from a reference curve than with qualitative grade score results but at present there are no internationally recognised IgE antibody Standards that have been calibrated for any allergen specificity. It is therefore not possible to determine a "true value" for any serum specimen and to permit the assessment of analytical sensitivities of the various assays.
Therefore at the present time we are limited to an assessment of a laboratories performance using a comparison of results by those laboratories using the same method and hence a designated value; of the "method mean" is used for eaeh method. Despite the great Variation in re-Tab. 5 Results in grades to Dl in two serum pools by method and for two distribution numbers. Table 7 shows mean running variance index scores divided into the above categories and by country for all the allergen specificities circulated during 1992.
With a chosen coefFicient of Variation of 15% for allergen specificities it was heartening to see the majority of laboratories with mean running variance index scores of < 200 for all allergens. As a measure of overall analytical performance overall mean running variance index score was used with a "moving window" of the last 24 results regardless of allergen specificity and again äs with mean running variance index score it was decided to classify performance in just the same way and table 8 shows the number of laboratories in each classification and then divided by country. More than 70% of participants had overall mean running variance index scores of < 200 with little difference by country: with this method of "scoring" only being started in 1992 it is a little early yet to see if participants are showing improvements in overall performance.
Discussion ii
Although the numerical results for each method vary it was hoped that a comparisön could be done using a weighting factor but is was then obvious that the dose responses between allergen specificities differed between methods. This problem can be shown by comparing the ratio of results using method mean values for the different allergen specificities expressed äs a ratio of two methods (see tab. 6).
Results in units varied greatly between the methods in use, so the all laboratory trimmed mean was not used to evaluate performance criteria and also because of the differences in results between allergens it was necessary to assess laboratory performance by allergen. Therefore the variance index scoring system was to be used based on a designated value for each method, for results to each allergen in each serum pool. A mean running variance index: score was calculated for each allergen specificity for each laboratory based on the last 4 results a laboratory returned to that allergen -henee it portrayed a "moving window" performance. A classification of performance based on arbitrary Separation of mean running variance index scores was established äs follows:
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Although EQA schemes for specific IgE have been organised in each of the three participating countries (UK, Belgium and the Netherlands) for a number of years very successfully they all feit that an expansion into a "Euro scheine" would be beneficial for the participants and also in terms of the expanded database. Hence 1992 saw the launch of a joint co-operation scheme with common serum pools, common distribution and reporting dates and a common Euro report. This was made possible by maintaining the national identity and Organisation of each scheme and also excellent co-operin the Organisation and administration by the three national organisers. The choice of specific IgE antibodies to test against was restricted in the first instance to the 8-10 most common allergens occurring in Western Europe and the choice was borae out by the good analysis frequency of almost all the allergens in circulation; the exception being the mould Aliernaria (M6) which was analysed by much fewer of the participants than M3 or the other allergens.
The scheme äs a whole has been enthusiastically received (even äs a subscription-based scheme) and has shown an increase in membership from 1992 to the beginning of 1993 for all three countries. We are currently exploring the possibility of inviting further countries in Western Europe to participate -the advantage of this scheme over others is that it is open to all types of laboratories regardless of the metfaod of analysis they use.
One of the advantages of a Euro scheme over a national one was thought to be the greater database of lesser known methods but we found a movement towards greater use of the Pharmacia CAP method during the year and thus the number of participants using some of the other commercial methods is still very small (i. e. < 5 or 6 users). Specific IgE analysis is in reality a multi-analyte System where the antibodies to each different allergen should be considered äs separate analytes despite some common features such äs solid phase and 2nd antibody and because of this the EQ A scheme is far more complex than thät of other analytes and schemes. Thus analysis of overall results should be treated with great caution.
The purification of allergens and preparation of protein extracts can vary between different commercial suppliers and then the types of solid phases for the binding of these extracts are also very varied between manufacturers. These variations coupled with differences in antibody production arid lack of international reference material makes the assay of specific IgE antibodies very complex and thus the use of EQA results in defining assay performance is just äs complex.
Because of these problems the first major criteria in data analysis and performance criteria was to decide to use method related niean results äs the designated values for variance index score calculations. Thus all laboratories would be compared to the designated values for their method for all allergens being tested and therefqre a performance criteria could be set for eäch method group.
Comparisons between methods should be treated with caution äs they would depend on whether an allergen was "recognised" äs positive or negative similarly by all methods. Sadly for the time being this scheme is reälly unable to directly compare results in any way between manufacturers and' even between different methods from the same manufacturer. This pröblem is aptly shown by comparing the responses to "hoüse dust mite" by the Pharmacia CAP and 1 DPC Alastat methods in serum pools SP01 and SP04. The usefulness in examining results by grades or classes and units is leading to the belief that clinical performance criteria could be established using a consensus result in grades and results in units whilst not comparable between methods could be used to calculate mean running variance index score and overall mean running variance index score which are a measure of analytical performance.
Conclusions and Future
1)
Interest in an external quality assessment scheme organised on a multi-national basis is gaining with increases in membership within each of the three participating countries.
2) There is a need to enlarge our result database by country and by method (especially methods with currently small numbers of users).
3) The ränge of allergens used for testing is still to be restricted to the 8-10 most commonly requested allergens in Western Europe.
4) It was also considered usefiil to test against 2-3 of the most common allergens at more than one antibody concentration.
5) It appears a usefiil experiment to add recovery experiments to allergens such äs Dl, El or T3 using a serum pool diluted to 3 or 4 antibody concentration levels.
6) We will continue to use äs the designated value for any result the method related trimmed mean because of the great Variation in results between methods.
7) Progress will be made in separating criteria of performance into clinical and analytical whereby clinical performance by judged by the results in grades and analytical performance by the results in units.
8) Mean running variance index score and overall mean running variance index score will continue to be used to compare the performance of laboratories analytical results in 9) It may be necessary to install different chosen coefficient of Variation for each allergen depending on the quality and Variation of results between allergens.
10) Changes in the data handling of results to grass and tree pollens may be necessary to separate results to mixed and single allergens.
11) It is hoped that by speedier transference of data i t will be possible to issue regulär reports to participants quicker than at present.
12) Attempts to help improve standardisation and harmonisation of specific IgE assays will be continued.
